Tyra Biosciences, Inc. (TYRA) shareholders
Close on Nov 17, 2026Market cap $1.17BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (19.90%), Rajeev Shah (19.90%) and 1 more | 14,130,492 | 19.90% | 13D (active) amendment | Sep 15, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (22.40%), Peter Kolchinsky (22.40%) and 1 more | 11,899,788 | 22.40% | 13D (active) amendment | Jun 4, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (14.40%) | 7,747,648 | 14.40% | 13G (passive) | Mar 31, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (6.10%), Bvf Inc/Il (6.10%) and 1 more | 4,215,886 | 6.10% | 13G (passive) | Sep 14, 2026 |
| Bvf Inc/Il Joint filing with Bvf Partners L P/Il (7.80%), Lampert Mark N (7.80%) and 1 more | 3,944,194 | 7.80% | 13G (passive) amendment | Dec 31, 2024 |
| Janus Henderson Group PLC | 3,890,589 | 7.20% | 13G (passive) amendment | Mar 31, 2026 |
| Saito Edric C. Joint filing with Wehrly, Mark C. (6.60%), Dapice Joshua J. (6.60%) and 13 more | 3,580,818 | 6.60% | 13G (passive) amendment | Mar 31, 2026 |
| Nextech VI GP S.a. r.l. Joint filing with Nextech VI Oncology SCSp (6.00%), Ian Charoub (6.00%) and 2 more | 3,553,585 | 6.00% | 13G (passive) amendment | Jun 30, 2026 |
| Senai Asefaw, M.D. Joint filing with Paradigm BioCapital Advisors LP (5.80%), Paradigm BioCapital Advisors GP LLC (5.80%) and 1 more | 3,473,453 | 5.80% | 13G (passive) | Sep 10, 2026 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (6.30%), Robert Egen Atkinson (6.30%) and 1 more | 3,375,000 | 6.30% | 13G (passive) amendment | Sep 30, 2025 |
| Dapice Joshua J. Joint filing with Wehrly, Mark C. (5.60%), Dreyfuss, Philip D. (5.60%) and 13 more | 2,984,818 | 5.60% | 13G (passive) | Feb 12, 2026 |
| Canaan XI L.P. Joint filing with Canaan Partners XI LLC (5.50%) | 2,930,444 | 5.50% | 13G (passive) amendment | Dec 31, 2025 |
| TCG Crossover GP I, LLC Joint filing with TCG Crossover Fund I, L.P. (5.70%), Chen Yu (5.70%) | 2,898,103 | 5.70% | 13G (passive) | Feb 27, 2025 |
| Aaron I. Davis | 2,548,905 | 5.00% | 13D (active) amendment | Dec 4, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TYRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,198,625 | 20.44% | $389.62M | – | 3.39% |
| FMR LLC | 8,920,513 | 14.95% | $284.92M | +1,172,865 | 0.01% |
| Jupiter Topco LLC | 4,352,448 | 7.29% | $139.16M | New | 0.06% |
| Alta Partners Management Company, L.P. | 3,823,425 | 6.41% | $122.12M | – | 95.92% |
| Nextech Invest, Ltd. | 3,553,585 | 5.95% | $113.50M | −502,276 | 5.39% |
| TCG Crossover Management, LLC | 3,248,980 | 5.44% | $103.77M | – | 2.49% |
| BlackRock, Inc. | 3,031,972 | 5.08% | $96.84M | +814,043 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,782,567 | 4.66% | $88.88M | +1,796,506 | 0.01% |
| State Street Corp | 2,140,368 | 3.59% | $68.36M | +924,290 | 0.00% |
| Commodore Capital LP | 1,875,000 | 3.14% | $59.89M | −600,000 | 3.57% |
| Paradigm Biocapital Advisors LP | 1,828,607 | 3.06% | $58.41M | −226,384 | 1.09% |
| Vanguard Capital Management LLC | 1,508,447 | 2.53% | $48.18M | +382,477 | 0.00% |
| Bvf Inc/Il | 1,476,196 | 2.47% | $47.15M | −500,000 | 1.21% |
| 5AM Venture Management, LLC | 1,029,298 | 1.72% | $32.88M | – | 11.42% |
| Deerfield Management Company, L.P. (Series C) | 1,017,000 | 1.70% | $32.48M | +468,000 | 0.34% |
| Hood River Capital Management LLC | 1,016,775 | 1.70% | $32.48M | New | 0.24% |
| Geode Capital Management, LLC | 970,734 | 1.63% | $31.01M | +312,252 | 0.00% |
| Caligan Partners LP | 806,986 | 1.35% | $25.78M | −469,982 | 1.21% |
| Canaan Partners XI LLC | 750,000 | 1.26% | $23.96M | – | 18.82% |
| Siren, L.L.C. | 725,000 | 1.21% | $23.16M | New | 0.47% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 170 | 69M | 100.0% | 33 / 73 | 44 / 25 | 17M | 10M |
| Q1 2026 | 164 | 66M | 100.0% | 46 / 60 | 35 / 14 | 22M | 11M |
| Q4 2025 | 133 | 57M | 95.2% | 29 / 43 | 38 / 10 | 6M | 4M |
| Q3 2025 | 116 | 56M | 93.4% | 9 / 41 | 37 / 14 | 2M | 3M |
| Q2 2025 | 121 | 57M | 94.9% | 18 / 62 | 20 / 14 | 7M | 4M |
| Q1 2025 | 117 | 54M | 89.8% | 22 / 42 | 31 / 16 | 13M | 4M |
| Q4 2024 | 113 | 49M | 81.5% | 36 / 34 | 25 / 18 | 12M | 11M |
| Q3 2024 | 95 | 47M | 79.5% | 25 / 29 | 20 / 8 | 4M | 2M |
| Q2 2024 | 79 | 47M | 79.1% | 18 / 30 | 17 / 16 | 3M | 3M |
| Q1 2024 | 77 | 47M | 79.3% | 22 / 26 | 15 / 7 | 12M | 1M |
| Q4 2023 | 62 | 36M | 60.7% | 9 / 21 | 12 / 6 | 1M | 2M |
| Q3 2023 | 59 | 36M | 61.1% | 4 / 16 | 16 / 4 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
187 funds held TYRA in Q2 2026, 30% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TYRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity OTC Portfolio | 3,295,446 | 5.52% | $105.06M | 0.24% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,392,376 | 2.33% | $44.47M | 0.41% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,135,472 | 1.90% | $36.27M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 944,201 | 1.58% | $30.16M | 0.04% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 793,140 | 1.33% | $25.33M | 0.17% | Jun 30, 2026 |
| Fidelity Advisor Equity Growth Fund | 678,600 | 1.14% | $22.67M | 0.17% | May 31, 2026 |
| VIP Growth Portfolio | 630,800 | 1.06% | $20.15M | 0.16% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 558,500 | 0.94% | $17.84M | 0.18% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 492,217 | 0.82% | $15.72M | 0.24% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 402,231 | 0.67% | $12.82M | 0.04% | Jul 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 389,800 | 0.65% | $12.43M | 0.17% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 374,540 | 0.63% | $11.94M | 0.14% | Jul 31, 2026 |
| Janus Henderson Triton Fund | 357,107 | 0.60% | $11.41M | 0.19% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 354,200 | 0.59% | $11.29M | 0.51% | Jul 31, 2026 |
| Fidelity Growth Discovery Fund | 341,700 | 0.57% | $10.91M | 0.16% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Todd Harris | President and CEO, Director | 1,438,495 | 2.41% | Sep 17, 2026 |
| Yuliya Rueb | Vice President, Finance (PAO) | 11,258 | 0.02% | Sep 17, 2026 |
| Alan Fuhrman | Chief Financial Officer | 37,115 | 0.06% | Sep 17, 2026 |
| Bhavesh Ashar | Chief Operating Officer | 15,013 | 0.03% | May 7, 2026 |
| Douglas J. Warner | Chief Medical Officer | 25,000 | 0.04% | May 7, 2026 |
| Daniel Bensen | Chief Discovery Officer | 146,981 | 0.25% | Feb 13, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 10,096,004 | 16.92% | Sep 17, 2026 |
| Rajeev M. Shah | Director, 10% owner | 8,477,275 | 14.21% | Sep 17, 2026 |
| Peter Kolchinsky | Director, 10% owner | 9,909,154 | 16.60% | Sep 17, 2026 |
| RA Capital Nexus Fund, L.P. | Director | 4,047,120 | 6.78% | Sep 17, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | 10,259,291 | 17.19% | Sep 17, 2026 |
| Rehan Verjee | Director | 972 | 0.00% | Sep 11, 2026 |
| Susan Moran | Director | 0 | – | Jun 1, 2026 |
| Adele M. Gulfo | Director | 4,000 | 0.01% | Jun 1, 2026 |
| Jake Simson | Director | – | – | Jun 1, 2026 |
| Stephen Michael Rothenberg | Director | 0 | – | Jun 1, 2026 |
| Robert J. More | Director | 3,823,425 | 6.41% | Jun 1, 2026 |
| Habib J. Dable | Director | 0 | – | Apr 20, 2026 |
| Gilla Kaplan | Director | 28,231 | 0.05% | Mar 27, 2026 |
| Nina S. Kjellson | Director | 4,144,590 | 6.95% | Feb 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yuliya Rueb Vice President, Finance (PAO) | Sep 15, 2026 | Award | +2,925 | $9.13 | $26.71K | 11,258 |
| Todd Harris President and CEO, Director | Sep 15, 2026 | Award | +864 | $9.13 | $7.89K | 1,438,495 |
| Alan Fuhrman Chief Financial Officer | Sep 15, 2026 | Award | +951 | $9.13 | $8.68K | 37,115 |
| Rehan Verjee Director | Sep 9, 2026 | Buy | +971.89 | $20.58 | $20.00K | 972 |
| Yuliya Rueb Vice President, Finance (PAO) | May 5, 2026 | Award | +8,333 | – | – | 43,354 |
| Todd Harris President and CEO, Director | May 5, 2026 | Award | +79,000 | – | – | 1,437,631 |
| Alan Fuhrman Chief Financial Officer | May 5, 2026 | Award | +20,000 | – | – | 36,164 |
| Douglas J. Warner Chief Medical Officer | May 5, 2026 | Award | +25,000 | – | – | 25,000 |
| Bhavesh Ashar Chief Operating Officer | May 5, 2026 | Award | +15,013 | – | – | 15,013 |
| Gilla Kaplan Director | Mar 26, 2026 | Returned to company | −53,172 | $37.75 | $2.01M | 28,231 |
| Gilla Kaplan Director | Mar 26, 2026 | Option exercise | −53,172 | $2.25 | $119.64K | 81,403 |
| Gilla Kaplan Director | Mar 25, 2026 | Option exercise | +14,295 | $2.25 | $32.16K | 42,526 |
| Gilla Kaplan Director | Mar 25, 2026 | Sale | −14,295 | $36.97 | $528.49K | 28,231 |
| Alan Fuhrman Chief Financial Officer | Mar 13, 2026 | Award | +1,376 | $9.13 | $12.56K | 16,164 |
| Todd Harris President and CEO, Director | Mar 13, 2026 | Award | +1,463 | $9.13 | $13.36K | 1,358,631 |
| Daniel Bensen Chief Discovery Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −5,872 | $33.37 | $195.95K | 146,981 |
| Daniel Bensen Chief Discovery Officer | Feb 12, 2026 | Sale(10b5-1 plan) | −2,128 | $31.50 | $67.03K | 152,853 |
| Daniel Bensen Chief Discovery Officer | Jan 12, 2026 | Sale(10b5-1 plan) | −1,017 | $29.08 | $29.57K | 154,981 |
| Daniel Bensen Chief Discovery Officer | Jan 12, 2026 | Sale(10b5-1 plan) | −6,983 | $28.44 | $198.60K | 155,998 |
| Robert J. More Director | Dec 19, 2025 | Sale(10b5-1 plan) | −10,000 | $25.00 | $250.00K | 3,823,425 |
| Daniel Bensen Chief Discovery Officer | Dec 12, 2025 | Sale(10b5-1 plan) | −8,000 | $22.64 | $181.12K | 162,981 |
| Robert J. More Director | Nov 21, 2025 | Sale(10b5-1 plan) | −246,871 | $20.25 | $5.00M | 3,833,425 |
| Daniel Bensen Chief Operating Officer | Nov 19, 2025 | Sale(10b5-1 plan) | −49,956 | $16.32 | $815.28K | 170,981 |
| Daniel Bensen Chief Operating Officer | Nov 18, 2025 | Sale(10b5-1 plan) | −75,633 | $16.07 | $1.22M | 220,937 |
| Daniel Bensen Chief Operating Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −18,572 | $16.11 | $299.19K | 298,070 |
| Daniel Bensen Chief Operating Officer | Nov 17, 2025 | Sale(10b5-1 plan) | −1,500 | $17.07 | $25.61K | 296,570 |
| Daniel Bensen Chief Operating Officer | Nov 14, 2025 | Sale(10b5-1 plan) | −110,228 | $16.02 | $1.77M | 316,642 |
| Daniel Bensen Chief Operating Officer | Nov 13, 2025 | Sale(10b5-1 plan) | −1,111 | $16.00 | $17.78K | 426,870 |
| Alan Fuhrman Chief Financial Officer | Sep 15, 2025 | Award | +701 | $9.13 | $6.40K | 14,788 |
| Gilla Kaplan Director | Jun 18, 2025 | Sale | −9,568 | $9.78 | $93.58K | 28,231 |
| Gilla Kaplan Director | Jun 17, 2025 | Sale | −10 | $10.35 | $104 | 37,799 |
| Gilla Kaplan Director | Jun 16, 2025 | Sale | −6,814 | $10.38 | $70.73K | 37,809 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 16, 2025 | Buy | +11,813 | $10.13 | $119.67K | 10,259,291 |
| Gilla Kaplan Director | Jun 13, 2025 | Sale | −15,000 | $10.31 | $154.65K | 44,623 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 13, 2025 | Buy | +120,167 | $10.20 | $1.23M | 10,247,478 |
| Gilla Kaplan Director | Jun 12, 2025 | Sale | −30,000 | $10.31 | $309.30K | 59,623 |
| Ra Capital Management, L.P. Director, 10% owner | Jun 12, 2025 | Buy | +31,307 | $10.20 | $319.33K | 10,127,311 |
| Capital Healthcare Fund LP RA Director, 10% owner | Jun 9, 2025 | Buy | +186,850 | $10.19 | $1.90M | 10,096,004 |
| Peter Kolchinsky Director, 10% owner | Jun 5, 2025 | Buy | +213,334 | $10.04 | $2.14M | 9,909,154 |
| Peter Kolchinsky Director, 10% owner | Jun 4, 2025 | Buy | +997,864 | $9.63 | $9.61M | 9,695,820 |
| Todd Harris President and CEO, Director | Mar 14, 2025 | Award | +1,241 | $9.78 | $12.14K | 1,357,168 |
| Alan Fuhrman Chief Financial Officer | Mar 14, 2025 | Award | +1,238 | $9.78 | $12.11K | 14,087 |
| Nina S. Kjellson Director | Feb 5, 2025 | Sale | −3,511 | $13.76 | $48.31K | 443,885 |
| Nina S. Kjellson Director | Feb 5, 2025 | Sale | −1,890 | $13.76 | $26.01K | 3,700,705 |
| Nina S. Kjellson Director | Jan 23, 2025 | Sale | −4,825 | $16.26 | $78.45K | 3,702,595 |
| Nina S. Kjellson Director | Jan 21, 2025 | Sale | −3,993 | $16.36 | $65.33K | 3,707,420 |
| Nina S. Kjellson Director | Jan 17, 2025 | Sale | −12,808 | $16.40 | $210.05K | 3,711,413 |
| Nina S. Kjellson Director | Jan 17, 2025 | Sale | −461 | $16.40 | $7.56K | 447,396 |
| Nina S. Kjellson Director | Jan 16, 2025 | Sale | −835 | $16.29 | $13.60K | 447,857 |
| Nina S. Kjellson Director | Jan 16, 2025 | Sale | −6,944 | $16.29 | $113.12K | 3,724,221 |
| Nina S. Kjellson Director | Nov 25, 2024 | Sale | −566 | $16.84 | $9.53K | 448,692 |
| Nina S. Kjellson Director | Nov 25, 2024 | Sale | −4,706 | $16.84 | $79.25K | 3,731,165 |
| Capital Healthcare Fund LP RA Director, 10% owner | Nov 8, 2024 | Buy | +1,220,681 | $16.25 | $19.84M | 8,697,956 |
| Nina S. Kjellson Director | Nov 7, 2024 | Sale | −19,720 | $17.32 | $341.55K | 3,735,871 |
| Nina S. Kjellson Director | Nov 7, 2024 | Sale | −2,371 | $17.32 | $41.07K | 449,258 |
| Nina S. Kjellson Director | Nov 6, 2024 | Sale | −5,635 | $17.18 | $96.81K | 451,629 |
| Nina S. Kjellson Director | Nov 6, 2024 | Sale | −46,856 | $17.18 | $804.99K | 3,755,591 |
| Nina S. Kjellson Director | Nov 5, 2024 | Sale | −1,126 | $16.77 | $18.88K | 457,264 |
| Nina S. Kjellson Director | Nov 5, 2024 | Sale | −9,367 | $16.77 | $157.08K | 3,802,447 |
| Nina S. Kjellson Director | Nov 4, 2024 | Sale | −116 | $17.01 | $1.97K | 458,390 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tyra Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,567 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Nextech Vi Oncology Scsp Shareholder | Jun 26, 2026 | 308,379 | $9.54M | Jun 26, 2026 | Private Placement |
| Nextech Vi Oncology Scsp Shareholder | Jun 1, 2026 | 300,000 | $10.02M | Jun 1, 2026 | Private Placement |
| Daniel Bensen Officer | May 12, 2026 | 8,000 | $274.00K | May 12, 2026 | Founders shares |
| Daniel Bensen Officer | Apr 13, 2026 | 8,000 | $285.00K | Apr 13, 2026 | Founders shares |
| Gilla Kaplan Director | Mar 26, 2026 | 53,172 | $2.01M | Mar 26, 2026 | Stock Option Exercise |
| Gilla Kaplan Director | Mar 25, 2026 | 14,295 | $528.51K | Mar 25, 2026 | Stock Option Exercise |
| Daniel Bensen Officer | Mar 12, 2026 | 8,000 | $283.00K | Mar 12, 2026 | Founders shares |
| Daniel Bensen Officer | Feb 12, 2026 | 8,000 | $262.00K | Feb 12, 2026 | Founders shares |
| Daniel Bensen Officer | Jan 12, 2026 | 8,000 | $232.00K | Jan 12, 2026 | Founders shares |
| Daniel Bensen Officer | Dec 12, 2025 | 8,000 | $180.00K | Dec 12, 2025 | Founders shares |
| Alta Partners NextGen Fund II, L.P. Affiliate | Nov 21, 2025 | 256,871 | $5.39M | Nov 21, 2025 | Private Placement |
| Daniel Bensen Officer | Nov 18, 2025 | 124,589 | $2.00M | Nov 18, 2025 | Founders shares |
| Daniel Bensen Officer | Nov 17, 2025 | 20,072 | $320.00K | Nov 17, 2025 | Founders shares |
| Daniel Bensen Officer | Nov 14, 2025 | 86,339 | $1.38M | Nov 14, 2025 | Founders shares |
| Daniel Bensen Officer | Nov 13, 2025 | 25,000 | $400.00K | Nov 13, 2025 | Founders shares |
See a number that looks wrong?